Filtered By:
Therapy: Endocrine Therapy
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 2859 results found since Jan 2013.
The beneficial effects of tamoxifen on arteries: a key player for cardiovascular health of breast cancer patient
Biochem Pharmacol. 2023 Jul 5:115677. doi: 10.1016/j.bcp.2023.115677. Online ahead of print.ABSTRACTBreast cancer is the most common cancer in women. Over the past few decades, advances in cancer detection and treatment have significantly improved survival rate of breast cancer patients. However, due to the cardiovascular toxicity of cancer treatments (chemotherapy, anti-HER2 antibodies and radiotherapy), cardiovascular diseases (CVD) have become an increasingly important cause of long-term morbidity and mortality in breast cancer survivors. Endocrine therapies are prescribed to reduce the risk of recurrence and specific d...
Source: Biochemical Pharmacology - July 7, 2023 Category: Drugs & Pharmacology Authors: Morgane Davezac Cecile Meneur Melissa Buscato Rana Zahreddine Jean-Fran çois Arnal Florence Dalenc Fran çoise Lenfant Coralie Fontaine Source Type: research
The beneficial effects of tamoxifen on arteries: A key player for cardiovascular health of breast cancer patient
Biochem Pharmacol. 2023 Jul 5;214:115677. doi: 10.1016/j.bcp.2023.115677. Online ahead of print.ABSTRACTBreast cancer is the most common cancer in women. Over the past few decades, advances in cancer detection and treatment have significantly improved survival rate of breast cancer patients. However, due to the cardiovascular toxicity of cancer treatments (chemotherapy, anti-HER2 antibodies and radiotherapy), cardiovascular diseases (CVD) have become an increasingly important cause of long-term morbidity and mortality in breast cancer survivors. Endocrine therapies are prescribed to reduce the risk of recurrence and specif...
Source: Biochemical Pharmacology - July 7, 2023 Category: Drugs & Pharmacology Authors: Morgane Davezac Cecile Meneur Melissa Buscato Rana Zahreddine Jean-Fran çois Arnal Florence Dalenc Fran çoise Lenfant Coralie Fontaine Source Type: research
FOXC1 and SOX10 in Estrogen Receptor-Low Positive/HER2-Negative Breast Cancer: Potential Biomarkers for the Basal-like Phenotype Prediction
CONCLUSIONS.—: ER-low positive breast cancers biologically overlap more with ER-negative tumors. ER-low positive/HER2-negative cases demonstrate a high rate of FOXC1 or SOX10 expression, and these cases might be better categorized as a basal-like phenotype/subtype. FOXC1 and SOX10 testing may be used for the intrinsic phenotype prediction for ER-low positive/HER2-negative patients.PMID:37406289 | DOI:10.5858/arpa.2022-0370-OA
Source: Archives of Pathology and Laboratory Medicine - July 5, 2023 Category: Laboratory Medicine Authors: Ming Li Shuling Zhou Hong Lv Mengyuan Cai Xiaochun Wan Hongfen Lu Ruohong Shui Wentao Yang Source Type: research
Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
We present a case of a patient with hormone-sensitive HER2 low metastatic breast cancer who underwent circulating tumor DNA next-generation sequencing to better inform her treatment options after progression on first-line therapy with a CDK 4/6 inhibitor and aromatase inhibitor. Our clinical approach in this patient population prioritizes the identification of actionable mutations with high-quality evidence for efficacy on the basis of clinical trials post-CDK 4/6 inhibitors, while balancing comorbidities and patient priorities for care. Several recent clinical trials discussed herein present clinically meaningful results ...
Source: Clinical Genitourinary Cancer - July 5, 2023 Category: Cancer & Oncology Authors: Emily B Jackson Stephen K L Chia Source Type: research
FOXC1 and SOX10 in Estrogen Receptor-Low Positive/HER2-Negative Breast Cancer: Potential Biomarkers for the Basal-like Phenotype Prediction
CONCLUSIONS.—: ER-low positive breast cancers biologically overlap more with ER-negative tumors. ER-low positive/HER2-negative cases demonstrate a high rate of FOXC1 or SOX10 expression, and these cases might be better categorized as a basal-like phenotype/subtype. FOXC1 and SOX10 testing may be used for the intrinsic phenotype prediction for ER-low positive/HER2-negative patients.PMID:37406289 | DOI:10.5858/arpa.2022-0370-OA
Source: Archives of Pathology and Laboratory Medicine - July 5, 2023 Category: Laboratory Medicine Authors: Ming Li Shuling Zhou Hong Lv Mengyuan Cai Xiaochun Wan Hongfen Lu Ruohong Shui Wentao Yang Source Type: research
Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
We present a case of a patient with hormone-sensitive HER2 low metastatic breast cancer who underwent circulating tumor DNA next-generation sequencing to better inform her treatment options after progression on first-line therapy with a CDK 4/6 inhibitor and aromatase inhibitor. Our clinical approach in this patient population prioritizes the identification of actionable mutations with high-quality evidence for efficacy on the basis of clinical trials post-CDK 4/6 inhibitors, while balancing comorbidities and patient priorities for care. Several recent clinical trials discussed herein present clinically meaningful results ...
Source: Clinical Breast Cancer - July 5, 2023 Category: Cancer & Oncology Authors: Emily B Jackson Stephen K L Chia Source Type: research
FOXC1 and SOX10 in Estrogen Receptor-Low Positive/HER2-Negative Breast Cancer: Potential Biomarkers for the Basal-like Phenotype Prediction
CONCLUSIONS.—: ER-low positive breast cancers biologically overlap more with ER-negative tumors. ER-low positive/HER2-negative cases demonstrate a high rate of FOXC1 or SOX10 expression, and these cases might be better categorized as a basal-like phenotype/subtype. FOXC1 and SOX10 testing may be used for the intrinsic phenotype prediction for ER-low positive/HER2-negative patients.PMID:37406289 | DOI:10.5858/arpa.2022-0370-OA
Source: Archives of Pathology and Laboratory Medicine - July 5, 2023 Category: Laboratory Medicine Authors: Ming Li Shuling Zhou Hong Lv Mengyuan Cai Xiaochun Wan Hongfen Lu Ruohong Shui Wentao Yang Source Type: research
Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
We present a case of a patient with hormone-sensitive HER2 low metastatic breast cancer who underwent circulating tumor DNA next-generation sequencing to better inform her treatment options after progression on first-line therapy with a CDK 4/6 inhibitor and aromatase inhibitor. Our clinical approach in this patient population prioritizes the identification of actionable mutations with high-quality evidence for efficacy on the basis of clinical trials post-CDK 4/6 inhibitors, while balancing comorbidities and patient priorities for care. Several recent clinical trials discussed herein present clinically meaningful results ...
Source: Clinical Breast Cancer - July 5, 2023 Category: Cancer & Oncology Authors: Emily B Jackson Stephen K L Chia Source Type: research
Atypical hyperplasia of the breast: Clinical cases and management strategies
Cleve Clin J Med. 2023 Jul 3;90(7):423-431. doi: 10.3949/ccjm.90a.22098.ABSTRACTAtypical hyperplasia of the breast is a histopathologic lesion identified incidentally on image-guided breast biopsy. It is associated with a substantial increase in lifetime risk for breast cancer. Clinicians should counsel women with atypical hyperplasia regarding risk-reducing strategies, which include preventive endocrine therapy options, enhanced surveillance imaging, and lifestyle modifications. In this review, we describe 5 different but common clinical case scenarios for atypical hyperplasia of the breast and review management strategie...
Source: Clinical Breast Cancer - July 3, 2023 Category: Cancer & Oncology Authors: Suneela Vegunta Dawn M Mussallem Aparna S Kaur Sandhya Pruthi Christine L Klassen Source Type: research
